Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug screening model for treating arrhythmia diseases

An arrhythmia and drug technology, applied in the direction of determination/examination of animal cells, vertebrate cells, microorganisms, etc., can solve the problems of malignant arrhythmia, side effects and toxic reactions, and achieve a feasible technical route, clear drug action targets, The novel effect of screening drug concept

Inactive Publication Date: 2011-04-20
中国人民解放军第三0九医院
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, because we do not really understand the cause of arrhythmia, the curative effect of antiarrhythmic drugs currently used clinically is not very good, and the side effects and toxic reactions are very large. Most antiarrhythmic drugs have the possibility of causing malignant arrhythmia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug screening model for treating arrhythmia diseases
  • Drug screening model for treating arrhythmia diseases
  • Drug screening model for treating arrhythmia diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Embodiment 1, the screening model and its application of drug related to arrhythmia disease

[0034]1. Screening model for drugs related to arrhythmia diseases

[0035] (1) Composition and characterization

[0036] 1. Composition:

[0037] (1) The drug screening model consists of ventricular myocytes and a suspension medium, and the ventricular myocytes are suspended in the suspension medium.

[0038] (2) Among them, the ventricular myocytes meet the following conditions: 1) the ventricular myocytes within 6 hours after separation; 2) the ventricular myocytes are suspended in a medium similar to the ionic strength and composition of the tissue fluid, without external stimulation ( In the case of an external electric field), it does not shrink. (Medium similar to tissue fluid ionic strength and composition: NaCl 143-146mM, KCl 3.5-5mM, CaCl 2 2-3mM, the rest is water).

[0039] (3) Among them, the composition and concentration of the suspension medium are shown in ...

Embodiment 2

[0090] Embodiment 2, the mechanism demonstration of screening model

[0091] 1. Known properties of cardiomyocytes:

[0092] (1) Cardiomyocytes, like other cells such as red blood cells, show negative charge on the surface. According to known research results, it is believed that the source of negative charge is not limited to complex sugars on the surface, but also the participation of plasma membrane phospholipids. Since the surface of cardiomyocytes is negatively charged, it should have the same characteristics of colloidal particles as other cells such as red blood cells, that is, cations with equal electric charge are adsorbed around cardiomyocytes to form a surface electric double layer. Adsorbed cations are affected by electrostatic attraction and van der Waals force in distribution, forming two layers, that is, the adsorption layer near the cell surface; and the diffusion layer near the surface of the suspension medium. The adsorption layer is firmly adsorbed on the c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
viscosityaaaaaaaaaa
Login to View More

Abstract

The invention discloses a drug screening model for treating arrhythmia diseases. The drug screening model comprises in vitro cardiac myocytes and a suspending medium, wherein the suspending medium is formed by NaCl, CaCl2, KCl, glucose, hydroxypropyl methyl cellulose, hydroxyethyl piperazinyl ethanesulfonic acid and water. The concentration of the NaCl is 3.7 mM-88.8 mM in the suspending medium; the concentration of the CaCl2 is 0.08 mM-1.8 mM in the suspending medium; the concentration of the KCl is 3 mM-12 mM in the suspending medium; the concentration of the glucose is 108.1 mM-246 mM in the suspending medium; the concentration of the hydroxypropyl methyl cellulose is 0.5 mM-0.54 mM in the suspending medium; and the concentration of the hydroxyethyl piperazinyl ethanesulfonic acid is 20 mM in the suspending medium. Through experimental evidence, the drug screening model of the invention can be used for screening out propafenone and amiodarone (which are both conventional drugs for treating the arrhythmia diseases). Therefore, the drug screening model of the invention has wide application prospect in the field of screening the drugs for treating heart-related diseases.

Description

technical field [0001] The invention relates to a drug screening model for treating arrhythmia diseases. Background technique [0002] Cardiac arrhythmia refers to a disease in which the rhythm of the heart changes due to abnormalities in the generation or conduction of cardiac excitation. There are many types of arrhythmias, which can be roughly divided into abnormal sinus node excitation, ectopic excitation, ectopic rhythm, and conduction disorders. Arrhythmia ranks at the forefront of cardiovascular diseases both in terms of morbidity and mortality. People have been working hard to study and explore, trying to find a drug that can control arrhythmia and bring good news to mankind. However, because we do not really understand the cause of arrhythmia, the curative effect of antiarrhythmic drugs currently used clinically is not very good, and the side effects and toxic reactions are very large. Most antiarrhythmic drugs may cause malignant arrhythmias. The treatment of ar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/02C12N5/077
Inventor 周英
Owner 中国人民解放军第三0九医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com